MBTPS1 and myeloid sarcoma: The absolute risk of MME was low with fingolimod, the originally FDA-approved S1P modulator, at 1% annual incidence with exposure, with both diabetes and uveitis identified as risk factors for its development.45 These risk factors for S1P-associated MME furthered the hypothesis that vascular permeability may be playing a significant role in the pathophysiology of MME for most MS patients.